Aducanumab is a recombinant human monoclonal antibody that selectively targets the amyloid-β (Aβ) peptide aggregates thought to play a part in the neurodegenerative process in Alzheimer's disease. Several Alzheimer's disease drugs have failed in development in recent years - including other anti-amyloid antibodies - so there is intense interest in any new developments. A new study reports interim results from a clinical trial of monthly infusions of aducanumab in subjects with prodromal or mild Alzheimer's disease. Treatment with aducanumab reduced brain Aβ plaques, an action accompanied by a dose-dependent slowing of clinical decline. The trial data support further development of aducanumab as an Aβ-removing therapy.
- Attack on amyloid-β protein (News & Views p36, doi: 10.1038/537036a)
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease (Article p50, doi: 10.1038/nature19323)
Recent Hot Topics
Sign up for Nature Research e-alerts to get the lastest research in your inbox every week.